OBJECTIVE: @entity1769 is the only medication widely used to promote @entity344 in the USA. Despite its appreciable @entity149 , it continues to be prescribed to @entity1 for chronic use. We sought to estimate the prevalence of chronic @entity1769 use among US @entity1 and identify the diagnoses that may have prompted this use. The US @entity1769 label lists only two indications in adults: symptomatic @entity354 ( @entity354 ) and @entity6 . The latter is rare in @entity1 so, in examining the indications likely to have prompted chronic @entity1769 use, we focused on @entity354 . METHODS: From two health services databases representing privately and publically insured @entity1 , respectively, we estimated the number of US @entity1 who used @entity1769 chronically and identified the diagnoses recorded at approximately the time when the chronic use began. We defined chronic use liberally as >= 35  days' supply, or conservatively as >= 130  days' supply in a 6-month period. For each chronic-use definition, insurance type, and age group, we estimated the proportion of @entity1 using @entity1769 chronically. We applied these proportions to US population estimates. RESULTS: Under the liberal and conservative definitions, respectively, 89,020 and 28,222 US @entity1 used @entity1769 chronically. CONCLUSION: In spite of its risk, substantial numbers of US @entity1 use @entity1769 chronically for symptoms suggestive of @entity354 .

Prevalence of Chronic XXXX Use and Associated Diagnoses in the US Pediatric Population.

@entity1 :: ('9606', 'Species') :: ['children'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic gastroparesis'] @entity149 :: ('MESH:D002493', 'Disease') :: ['risk of central nervous system complications'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal motility'] @entity1769 :: ('MESH:D008787', 'Chemical') :: ['Metoclopramide', 'metoclopramide'] @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux', 'GERD']
@entity1769 :: (MESH:D008787,Chemical) :: ['Metoclopramide']
